Arrowhead Pharmaceuticals (ARWR) said Tuesday it had filed a request for regulatory clearance to initiate a phase 1/2a clinical trial of its experimental therapy, ARO-ALK7, to treat obesity.
The company said the application was submitted to the New Zealand Medicines and Medical Devices Safety Authority for review.
It added pending approval, the company plans to evaluate the safety and tolerability of ARO-ALK7 in up to 90 adult volunteers with obesity.
The trial will consist of two parts, where the first part will assess single and multiple doses of ARO-ALK7 monotherapy, while the second part will evaluate ARO-ALK7 in combination with tirzepatide, an approved treatment for type 2 diabetes and weight management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.